Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P170030/S055

Orsiro Mission Sirolimus Eluting Coronary Stent System; Synsiro Pro Sirolimus Eluting Coronary Stent System

Biotronik AG · Decision date Aug 19, 2025

FDA DECISIONP170030/S055

What did the FDA approve?

FDA records P170030/S055 as a supplement to PMA P170030, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Aug 19, 2025.

FDA approval order statement

approval to introduce an additional trade name, Synsiro Pro, for the approved PMA device.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Cardiovascular
Decision date
Aug 19, 2025
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P170030/S055
Regulatory pathway
PMA supplement
Applicant
Biotronik AG
Product code
NIQ
Decision code
APPR
Decision date
Aug 19, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Coronary drug-eluting stent.

Applicant
Biotronik AG
Product code
NIQ
FDA device class
3

For the original device and its historical approval scope, see PMA P170030. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P170030 · Original PMA

    ORSIRO Sirolimus Eluting Coronary Stent System

  2. P170030/S055 received

    Application receipt date recorded by FDA.

  3. P170030/S055 · FDA decision

    Real-Time Process

  4. P170030/S056 · Related supplement

    Orsiro Mission Sirolimus Eluting Coronary Stent System

  5. P170030/S059 · Related supplement

    Orsiro Mission Sirolimus Eluting Coronary Stent System, Synsiro Pro Sirolimus Eluting Coronary Stent System

  6. P170030/S060 · Related supplement

    Orsiro Mission Sirolimus Eluting Coronary Stent System; Synsiro Pro Sirolimus Eluting Coronary Stent System

  7. P170030/S061 · Related supplement

    ORSIRO Sirolimus Eluting Coronary Stent System; Synsiro Pro Sirolimus Eluting Coronary Stent System

  8. P170030/S047 · Related supplement

    Orsiro Mission Sirolimus Eluting Coronary Stent System

  9. P170030/S062 · Related supplement

    ORSIRO Sirolimus Eluting Coronary Stent System

  10. P170030/S052 · Related supplement

    Orsiro Mission Sirolimus Eluting Coronary Stent System

  11. P170030/S058 · Related supplement

    Orsiro Mission Sirolimus Eluting Coronary Stent System

  12. P170030/S064 · Related supplement

    Orsiro Mission larger diameter stents Ø 4.5 5.0 mm

  13. P170030/S065 · Related supplement

    ORSIRO Sirolimus Eluting Coronary Stent System

  14. P170030/S066 · Related supplement

    ORSIRO Sirolimus Eluting Coronary Stent System

Timeline entries are records held by MedtechLedger for P170030. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P170030

Explore the linked device profile

Other records with product code NIQ

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik AG

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Ackerstrasse 6, Bülach, 8180

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records